Midatech Pharma PLC ADR (MTP) Stock
MTP is no longer traded. Midatech Pharma PLC ADR was delisted from the Nasdaq in May 2023.
Prices on this page are historical; the last trade was May 26, 2023 at $0.13.
Midatech Pharma PLC ADR stock price history
MTP final trading statistics
- Final close
- $0.13
- Final trading day
- May 26, 2023
- Market cap at delisting
- $1.98M
- Shares outstanding
- 6.93M
- Final 52-week range
- $0.12 – $2.81
- Avg. volume (final 3 mo.)
- 2,754,973
- All-time high (split-adj.)
- $1000000.00 · Dec 2015
- All-time low (split-adj.)
- $10.52 · May 2023
- Return since IPO
- -100.0%
- Beta
- 1.22
- Book value / share
- $7.61
- Price / book
- 0.02
Midatech Pharma PLC ADR annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $699.0K | -$7.7M | — |
| FY2021 | $578.0K | -$5.5M | — |
| FY2020 | $343.0K | -$22.2M | -$0.54 |
| FY2019 | $674.0K | -$9.1M | -$198.82 |
| FY2018 | $149.0K | -$15.0M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Midatech Pharma PLC ADR
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Midatech Pharma PLC ADR stock FAQ
What happened to Midatech Pharma PLC ADR stock?
Midatech Pharma PLC ADR stock was delisted from the Nasdaq. Its final close was $0.13 on May 26, 2023.
Is MTP stock still trading?
No. MTP was delisted from the Nasdaq in May 2023 and no longer trades on a U.S. exchange.
What was the last price of MTP stock?
MTP closed at $0.13 on its final trading day, May 26, 2023, for a market value of about $1.98M.
What were Midatech Pharma PLC ADR's revenue and earnings in its last full fiscal year?
Midatech Pharma PLC ADR reported revenue of $699.0K and net income of -$7.7M in fiscal 2022, its last full year as a public company.
When did Midatech Pharma PLC ADR go public?
Midatech Pharma PLC ADR stock began trading on December 7, 2015.